To Evaluate Efficacy And Safety Of Mmc After Excision Of Ocular Surface Squamous Neoplasia With Conjunctival Autograft

Purpose:  This study was conducted to determine the treatment of histologically confirmed ocular surface squamous neoplasia by excision with conjunctival auto graft, and Mitomycin C. Methods: A clinical study of 19 eyes of 19 patients in which excision with conjunctival autograft of ocular surface squamous neoplasia was done and treated with Mitomycin C 0.04% eye drop daily for two to three alternate seven day courses according to the protocol. All patients had weekly follow-up visits till the end of the treatment course, then biweekly visits for three months, and finally monthly visits thereafter. Results: The mean ± SD follow-up period was 39.4±15.3 months (range 06-56 months). Four patients (21.05%) experienced recurrence after the initial treatment; three of them responded to re-treatment and were disease-free, thereafter, till the end of follow-up. Survival analysis with Kaplan-Meier was 94.74%, non-recurrence for 36 months (mean 37.83 months with S.D of 14.73) of follow-up. All patients reported mild to moderate redness and irritation which were controlled with lubricants and mild corticosteroid eye drops. No serious ocular or systemic side effects were seen. Conclusion: Mitomycin C (0.04%) drops used daily for two to three alternate seven day courses were found to be safe and effective with lower recurrence rate for ocular surface squamous neoplasia (OSSN).